Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for type 2 diabetes
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
The Effect of Sleep Hygiene Education on Sleep Quality in Children with Type 1 Diabetes Mellitus: A Preliminary Study. To identify the effect of sleep hygiene education on sleep quality in children with Type 1 Diabetes Mellitus (T1DM), a quasi-experiment with control group and pretest-posttest design was conducted. Samples of 46 children with T1DM in IKADAR were assigned into intervention (n = 23) and control (n = 23). The intervention group received sleep hygiene education for 10 minutes via
Implementation and fidelity of a participatory learning and action cycle intervention to prevent and control type2diabetes in rural Bangladesh. There is an urgent need to address the growing type2diabetes disease burden. 20-30% of adults in rural areas of Bangladesh have intermediate hyperglycaemia and about 10% have diabetes. We report on the implementation and fidelity of a Participatory Learning and Action (PLA) intervention, evaluated through a three-arm cluster randomised controlled (...) trial which reduced the incidence of diabetes and intermediate hyperglycaemia in rural Bangladesh. PLA interventions have been effective in addressing population level health problems in low income country contexts, and therefore we sought to use this approach to engage communities to identify and address community barriers to prevention and control of type2 diabetes.We used a mixed methods approach collecting quantitative data through field reports and qualitative data through observations
Efficacy of a Lupinus mutabilis Sweet snack as complement to conventional type2diabetes mellitus treatment. Introduction: therapeutic lifestyles changes including frequent consumption of legumes have resulted in improved metabolic control and decreased blood pressure in type2diabetes-mellitus (T2DM) patients. Objective: this was a quasi-experimental-28-week crossover-study that assessed the effect of daily consumption of the legume Lupinus mutabilis (LM) on metabolic control of T2DM
Comparison of Major Adverse Cardiac Events Between Instantaneous Wave-Free Ratio and Fractional Flow Reserve-Guided Strategy in Patients With or Without Type2Diabetes: A Secondary Analysis of a Randomized Clinical Trial. Invasive physiologic indices such as fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) are used in clinical practice. Nevertheless, comparative prognostic outcomes of iFR-guided and FFR-guided treatment in patients with type2diabetes have not yet been (...) of deferral of revascularization than the FFR-guided group (56.5% [n = 477 of 844] vs 46.6% [n = 402 of 863]; P < .001). However, it was not different between the 2 groups in the diabetes population (42.1% [n = 161 of 382] vs 47.1% [n = 177 of 376]; P = .15). At 1 year, the diabetes population showed a significantly higher rate of MACE than the nondiabetes population (8.6% vs 5.6%; adjusted hazard ratio [HR], 1.88; 95% CI, 1.28-2.64; P < .001). However, there was no significant difference in MACE rates
Associations of Fenofibrate Therapy WithÂ Incidence and Progression of CKD inÂ Patients With Type2Diabetes. Abnormalities in lipid metabolism may contribute to the development and progression of chronic kidney disease (CKD) in patients with type2diabetes. Fenofibrate induces early and reversible reduction in estimated glomerular filtration rate (eGFR), but it may have protective effects on microvascular complications of diabetes. We hypothesized that randomization to fenofibrate versus (...) placebo would be associated with beneficial long-term effects on kidney outcomes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial participants.We conducted a post hoc analysis in the ACCORD Lipid Trial to examine the association of randomization to fenofibrate versus placebo with change in eGFR and with time-to-development of microalbuminuria, macroalbuminuria, CKD, and kidney failure.We analyzed 2636 participants in the fenofibrate arm and 2632 in the placebo arm. During
Liraglutide (Victoza) - type2diabetes Cost-effectiveness of liraglutide (Victoza®) for the treatment of adults with insufficiently controlled type2diabetes as an adjunct to diet and exercise. The NCPE has issued a recommendation regarding the cost-effectiveness of liraglutide (Victoza®). Following assessment of the applicant’s submission, the NCPE recommends that liraglutide (Victoza®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing (...) be conducted. In September 2017, Novo Nordisk Ltd submitted a dossier to support the comparative clinical effectiveness and cost-effectiveness of liraglutide (Victoza®) for the treatment of adults with insufficiently controlled type2diabetes mellitus as an adjunct to diet and exercise either: ? as monotherapy when metformin is considered inappropriate due to intolerance or contraindications; or ? in addition to other medicinal products for the treatment of type2diabetes In their submission, Novo
Ertugliflozin (Steglatro) - type2diabetes mellitus 1 Published 14 January 2019 1 SMC2102 ertugliflozin 5mg, 15mg film-coated tablet (Steglatro®) Merck Sharp & Dohme 7 December 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission ertugliflozin (Steglatro ® ) is accepted (...) for restricted use within NHSScotland. Indication under review: in adults aged 18 years and older with type2diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: ? As monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. ? In addition to other medicinal products for the treatment of diabetes. SMC restriction: ertugliflozin is accepted for use as monotherapy and as add-on therapy. When used as monotherapy
Semaglutide (Ozempic) - the treatment of adults with insufficiently controlled type2diabetes mellitus (T2DM) as an adjunct to diet and exercise 1 Published 14 January 2019 1 SMC2092 semaglutide 0.25mg, 0.5mg and 1mg solution for injection in pre-filled pen (Ozempic®) Novo Nordisk Ltd. 9 November 2018 (Issued 7 December 2018) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its (...) use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission semaglutide (Ozempic ® ) is accepted for restricted use within NHSScotland. Indication under review: the treatment of adults with insufficiently controlled type2diabetes mellitus (T2DM) as an adjunct to diet and exercise: ? As monotherapy when metformin is considered inappropriate due to intolerance or contraindications ? In addition to other medicinal products for the treatment of diabetes. SMC
Type2diabetes: what's next after metformin? Type2diabetes: what's next after metformin? | NPS MedicineWise 20 Years Of Helping Australians Make Better Decisions About Medicines, Medical Tests And Other Health Technologies. Log in Facebook Twitter LinkedIn Google Signing you in Use another account OR Login Form Email Password Log in to NPS MedicineWise Forgot password Forgot password Email Send reset instructions Set new password Reset Password Password Set password Account exists We found (...) that match your past search terms. We’ll send you email alerts for articles that match these search terms: History Clear all to view your search history. Menu Breadcrumbs Type2diabetes: what's next after metformin? Type2diabetes: what's next after metformin? With a range of blood glucose-lowering medicines on the market, it can be hard to decide what to prescribe for patients needing more than metformin. Share Share to: Larger text Smaller text This program is funded by Boehringer Ingelheim Pty
Second-line Drug Therapy for Patients with Type2Diabetes Second-line drug therapy for patients with Type2Diabetes A Consensus Statement from the Kaiser Permanente National Integrated Cardiovascular Health (ICVH) Work Group November 19, 2018 The Kaiser Permanente ICVH group is aware of the new treatment recommendations published in the American Diabetes Association’s (ADA) Management of Hyperglycemia in Type2Diabetes 2018 Consensus Report. The ADA places newer diabetic medications (...) (including insulin) are evidence-based, of established efficacy, and are clinically appropriate in our patients with type2diabetes. We have commissioned an independent group to do a high-quality systematic review of these newer diabetic medications with results forthcoming within the next month. The National KP Diabetes recommendations will be formally updated following this comprehensive review of the literature and inter-regional vetting with clinical leads and National Guideline Directors (NGD
Minimed 670g - for the management of type 1 diabetes mellitus Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for the is located below. Updated: The following (...) table describes post-licensing activity for the . For more information on the type of information found in PLATs, please refer to the For additional information about the medical device application process, refer to the . Licence Number: Post-Licensing Activity Table (PLAT) Activity/Application Type, Application Number Date Submitted Decision and Date Summary of Activities 1 What was approved? Application Milestones: Application Milestone Date For additional information about the medical device
Cardiovascular Benefits and Harms of Step Therapy in the Treatment of Type2Diabetes in Adults with and without Atherosclerotic Cardiovascular Disease Cardiovascular Benefits and Harms of Step Therapy in the Treatment of Type2Diabetes in Adults with and without Atherosclerotic Cardiovascular Disease Kaiser Permanente Research Affiliates Evidence-based Practice Center Corinne Evans, MPP; Nicholas Emptage, MAE; Megan Rushkin, MPH; and Jennifer S. Lin, MD, MCR Summary Question 1. In persons (...) with type2diabetes with or without known atherosclerotic cardiovascular disease (ASCVD) who cannot attain adequate glucose control with metformin, what is the benefit of GLP-1 agonists or SGLT-2 inhibitors on cardiovascular morbidity and mortality? • Evidence of benefit in persons with known ASCVD on cardiovascular disease (CVD) outcomes, CVD mortality and all-cause mortality (ACM) o Based on limited evidence in persons without ASCVD, no evidence of benefit on CVD outcomes • Presumed class effect
Cardiovascular Risk Reduction in Patients with Type2Diabetes and Atherosclerotic Cardiovascular Disease EXPERT CONSENSUS DECISION PATHWAY 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type2Diabetes and Atherosclerotic Cardiovascular Disease A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways Endorsed by the American Diabetes Association Writing Committee Sandeep R. Das, MD, MPH (...) citedasfollows:Das SR,EverettBM,BirtcherKK,BrownJM,CefaluWT,Januzzi JL Jr, Rastogi Kalyani R, Kosiborod M, Magwire ML, Morris PB, Sperling LS. 2018 ACC expert consensus decision pathway on novel therapies for car- diovascular risk reduction in patients with type2diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 2018;XX:XXX–XXX. Copies:Thisdocumentisavailableonthewebsite oftheAmericanCollegeof
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type2Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA Individuals with type2diabetes mellitus are at increased risk for heart failure (HF), particularly those with coexisting atherosclerotic cardiovascular disease and/or kidney disease. Some but not all dipeptidyl peptidase-4 inhibitors have been associated with increased HF risk. We performed secondary analyses of HF and related outcomes (...) with the dipeptidyl peptidase-4 inhibitor linagliptin versus placebo in CARMELINA (The Cardiovascular and Renal Microvascular Outcome Study With Linagliptin), a cardiovascular outcomes trial that enrolled participants with type2diabetes mellitus and atherosclerotic cardiovascular disease and/or kidney disease.Participants in 27 countries with type2diabetes mellitus and concomitant atherosclerotic cardiovascular disease and/or kidney disease were randomized 1:1 to receive once daily oral linagliptin 5 mg
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type2diabetes To compare the efficacy and safety of an intensification strategy of early triple combination therapy with dapagliflozin (DAPA) plus saxagliptin (SAXA) to a dual therapy strategy with sitagliptin (SITA) in patients with type2diabetes who are inadequately controlled with metformin (MET) monotherapy.This
Systemic effects of periodontitis treatment in patients with type2diabetes: a 12 month, single-centre, investigator-masked, randomised trial Chronic inflammation is believed to be a major mechanism underlying the pathophysiology of type2diabetes. Periodontitis is a cause of systemic inflammation. We aimed to assess the effects of periodontal treatment on glycaemic control in people with type2 diabetes.In this 12 month, single-centre, parallel-group, investigator-masked, randomised trial (...) , we recruited patients with type2diabetes, moderate-to-severe periodontitis, and at least 15 teeth from four local hospitals and 15 medical or dental practices in the UK. We randomly assigned patients (1:1) using a computer-generated table to receive intensive periodontal treatment (IPT; whole mouth subgingival scaling, surgical periodontal therapy [if the participants showed good oral hygiene practice; otherwise dental cleaning again], and supportive periodontal therapy every 3 months until
Metformin Improves Insulin Sensitivity and Vascular Health in Youth With Type 1 Diabetes Mellitus Cardiovascular disease is the leading cause of mortality in type 1 diabetes mellitus (T1DM) and relates strongly to insulin resistance (IR). Lean and obese adolescents with T1DM have marked IR. Metformin improves surrogate markers of IR in T1DM, but its effect on directly measured IR and vascular health in youth with T1DM is unclear. We hypothesized that adolescents with T1DM have impaired vascular